PIPEDA Terms of Use Consent - Contact us form - english
PIPEDA Terms of Use Consent - Contact us form - english
Search
Terms of Use
Terms of Use
Innovative project launched using advanced digital technology to transform management of complex care for patients with heart failure
Innovative project launched using advanced digital technology to transform management of complex care for patients with heart failure
Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase
Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase
Contact Us
Queries and feedback
Human Health Partnering Connect with Us
Human Health Partnering Connect with Us
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales) More than 25 billion EUR investment in R&D and 7 billion EUR in capital expenditure over the next five years Human Pharma pipeline acceleration: up to 15 new product launches
New collaboration to improve the detection of type 2 diabetes in high-risk patients starts in Montreal, Quebec
The project will use artificial intelligence (A.I.), wearable technologies and electronic health record systems to identify patients who may have type 2 diabetes in Montreal, Quebec
New data presented at the ISTH 2015 Congress show Idarucizumab* results in immediate reversal of dabigatran in patients requiring urgent medical procedures or with serious bleeding complications1,2
New data presented at the ISTH 2015 Congress show Idarucizumab* results in immediate reversal of dabigatran in patients requiring urgent medical procedures or with serious bleeding complications1,2
Innovative health projects impact thousands of Indigenous Peoples in Canada
Innovative health projects impact thousands of Indigenous Peoples in Canada
Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalized pustular psoriasis
New clinical trial data published in the New England Journal of Medicine, showed that spesolimab, a novel IL-36R antibody treatment, was effective in rapidly treating adult patients with generalized pustular psoriasis (GPP) experiencing a flare.
Indigenous Peoples living with diabetes is the focus of four new health pilot projects in Ontario, Nunavut, Alberta, and Manitoba
Indigenous Peoples living with diabetes is the focus of four new health pilot projects in Ontario, Nunavut, Alberta, and Manitoba
Boehringer Ingelheim Animal Health Canada Inc. contributes to the development of the Centre of Excellence in Veterinary Interventional Medicine and Cardiology at CHUV
Boehringer Ingelheim Animal Health Canada Inc. contributes to the development of the Centre of Excellence in Veterinary Interventional Medicine and Cardiology at CHUV
Application Platform Data privacy statement
(Application Platform) Data Privacy Statement | Boehringer Ingelheim Careers and Job Opportunities
Virtual care pharmacy services offered in Alberta long-term care facilities
Virtual care pharmacy services offered in Alberta long-term care facilities
Code of Conduct
Our Code of Conduct sets the ethical standards that guides all our business activities. It´s about all of us. Each individual plays a vital role in bringing the Code of Conduct to live.
Breathing new life into patient care: Innovative partnership aims to transform interstitial lung disease support
Burlington, ON (October 25, 2023) – In a unique partnership, Boehringer Ingelheim (Canada) Ltd., St. Joseph's Healthcare Hamilton, and McMaster University have come together to transform the way patients are supported at the onset of a diagnosis
Meet our Team
Find all our contact information here as well as information on where you can meet us virtually or in person. You can also find out how to submit your opportunity to our BD&L team
Boehringer Ingelheim (Canada) Ltd. and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials
Boehringer Ingelheim (Canada) Ltd. and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials
New data showed OFEV® (nintedanib) slows decline of lung function in broad range of chronic fibrosing interstitial lung diseases with a progressive phenotype
New data showed OFEV® (nintedanib) slows decline of lung function in broad range of chronic fibrosing interstitial lung diseases with a progressive phenotype
Boehringer Ingelheim shares updated 2030 environmental sustainability commitments
Boehringer Ingelheim shares updated 2030 environmental sustainability commitments
Information Technology
IT
R&D - Transforming tomorrow
Manami Tsutsumi, Senior Associate Director in Research & Development describes what it's like working on the cutting edge of pharmaceutical development.
Health Canada issues Notice of Compliance (NOC) for Jardiance® (empagliflozin) for the treatment of heart failure with reduced ejection fraction
Health Canada issues Notice of Compliance (NOC) for Jardiance® (empagliflozin) for the treatment of heart failure with reduced ejection fraction
Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis